During a live event, Hannah Choe, MD, analyzed key findings from the AGAVE-201 trial of axatilimab in chronic graft-vs-host disease. A significant number of patients who develop chronic graft-vs-host ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback